CTIC


Stock Update (NASDAQ:CTIC): CTI BioPharma Corp Announces Positive Progress On Lead Programs

CTI BioPharma Corp (NASDAQ:CTIC) announced positive progress on its lead programs in addition to key business priorities for 2017. “Throughout 2016 we maintained …

Company Update (NASDAQ:CTIC): Here’s Why CTI BioPharma Corp Shares Are Soaring 18% Today

CTI BioPharma Corp (NASDAQ:CTIC) announced that the full clinical hold (February 2016) implemented by the U.S.

Stock Update (NASDAQ:CTIC): CTI BioPharma Corp Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting

CTI BioPharma Corp (NASDAQ:CTIC) announced that data from the randomized Phase 3 PERSIST-2 clinical trial comparing the investigational agent pacritinib, an oral multikinase …

Company Update (NASDAQ:CTIC): CTI BioPharma Corp Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

CTI BioPharma Corp (NASDAQ:CTIC) announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with …

Company Update (NASDAQ:CTIC): CTI BioPharma Corp Presented Long-Term Follow Up Data For Pacritinib At 2016 ASCO Annual Meeting

CTI BioPharma Corp (NASDAQ:CTIC) announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, …

Company Update (NASDAQ:CTIC): CTI BioPharma Corp Reports First Quarter 2016 Financial Results

CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the first quarter ended March 31, 2016. “We continue to believe in the potential of pacritnib …

Company Update (NASDAQ:CTIC): CTI BioPharma Corp Presents Preclinical Data of Pacritinib at AACR Annual Meeting 2016

CTI BioPharma Corp (NASDAQ:CTIC) announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be …

Company Update (NASDAQ:CTIC): CTI BioPharma Corp Reports Fourth Quarter And Full Year 2015 Results

CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the fourth quarter and full year ended December 31, 2015. “While we were disappointed and surprised …